Cell Bio Human Tech Co.,Ltd (KOSDAQ:318160)
South Korea · Delayed Price · Currency is KRW 6,370.00
+460.00 (7.78%)
At close: Aug 24, 2026
KOSDAQ:318160 Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 55,525 | 51,066 | 28,419 | 27,324 | 27,545 | 35,161 |
Revenue Growth | 80.57% | 79.69% | 4.00% | -0.80% | -21.66% | 22.99% |
Gross Profit Gross Profit Growth | 19,164 | 18,845 | 9,045 | 7,729 | 7,643 | 10,225 |
Operating Income Operating Income Growth | 9,308 | 9,317 | 4,037 | 3,149 | 3,535 | 5,610 |
Net Income Net Income Growth | 9,250 | 8,721 | 4,379 | -1,857 | 2,890 | 3,131 |
Earnings Per Share EPS Growth | 1106.43 | 1062.52 | 490.80 | -220.00 | 412.78 | 396.66 |
EPS Growth | 89.73% | 116.49% | - | - | 4.06% | -23.72% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 46,940 | 22,725 | 19,954 | 18,688 | 21,191 |
Asia Asia Growth | 32,211 | 19,219 | 14,277 | 15,946 | 14,505 |
Consolidation Consolidation Growth | -28,140 | -13,598 | -6,907 | -7,090 | -534.55 |
America America Growth | 54.1 | 73.22 | - | - | - |
Total Total Growth | 51,066 | 28,419 | 27,324 | 27,545 | 35,161 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 19,036 | 16,601 | 14,306 | 13,485 | 6,895 | 21,392 |
Total Debt Total Debt Growth | 21,052 | 20,510 | 4,068 | 5,927 | 5,232 | 14,663 |
Net Cash (Debt) Net Cash Growth | -2,017 | -3,909 | 10,238 | 7,558 | 1,663 | 6,728 |
Net Cash Growth | - | - | 35.46% | 354.48% | -75.28% | -43.71% |
Net Cash Per Share Net Cash Per Share Growth | -241.24 | -476.29 | 1147.60 | 894.55 | 237.54 | 852.31 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 3,048 | 1,487 | 9,271 | 1,759 | 437.8 | 7,614 |
Capital Expenditures CapEx Growth | -5,943 | -6,638 | -2,024 | -627.84 | -360.31 | -3,725 |
Free Cash Flow Free Cash Flow Growth | -2,895 | -5,151 | 7,247 | 1,131 | 77.49 | 3,889 |
Free Cash Flow Growth | - | - | 540.50% | 1360.05% | -98.01% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 34.51% | 36.90% | 31.83% | 28.29% | 27.75% | 29.08% |
Operating Margin | 16.76% | 18.25% | 14.21% | 11.53% | 12.83% | 15.96% |
Pretax Margin | 17.17% | 17.59% | 18.27% | -2.97% | 12.85% | 12.74% |
Profit Margin | 16.66% | 17.08% | 15.41% | -6.80% | 10.49% | 8.91% |
FCF Margin | -5.21% | -10.09% | 25.50% | 4.14% | 0.28% | 11.06% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 25, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.76 | 7.64 | 6.31 | - | - | - |
P/FCF Ratio | - | - | 3.82 | 33.46 | - | - |
PS Ratio | 0.96 | 1.31 | 0.97 | 1.39 | - | - |